Skin ConditionNCT06771388
Efficacy Evaluation of Avance QQ Collagen for Skin Beautification
A study testing Liposomal collagen drink and Non-liposomal collagen drink in people with Skin Condition and Liposomal Encapsulation, run by TCI Co., Ltd. at 1 site in Taiwan.
Trial summary
To assess Avance QQ Collagen product on skin condition improvement Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Condition, Liposomal Encapsulation
- What is being tested?
- Liposomal collagen drink and Non-liposomal collagen drink
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 75 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Nov 2024to 28 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy male or female adults, age above 18 years old;
- The grade of crow's feet above 2 (Han et al. Sci Rep 13, 18903 (2023));
- Commitment not to use products having activity comparable with that of the product to be tested during the study period;
- Free of any dermatological or systemic disorder that would interfere with results.
Who cannot join
- Subject with obvious skin surface damage;
- Subject who had oral or topical medication which may affect skin condition within 1 month;
- Subject who is a vegetarian or likely to be acutely allergic to the listed ingredients in the product;
- Female who is pregnant, nursing or planning to become pregnant during the course of the study;
- Received facial laser therapy, chemical peeling in the past 2 months.
Trial locations and contacts
1 site in 1 country.
About this study
To assess Avance QQ Collagen product on skin condition improvement
- Conditions
- Skin Condition, Liposomal Encapsulation
- Being tested
- Liposomal collagen drink, Non-liposomal collagen drink, Placebo drink
- Keywords
- Avance QQ Collagen, Double Nutri
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liposomal collagen drinkDietary supplement
Also called Avance QQ Collagen
consume 50 g liquid drink daily for 8 consecutive weeks
Non-liposomal collagen drinkDietary supplement
consume 50 g liquid drink daily for 8 consecutive weeks
Placebo drinkDietary supplement
consume 50 g liquid drink daily for 8 consecutive weeks
| Study group | Role | What they receive |
|---|---|---|
| Placebo drink | Placebo comparator | Not described Receives: Dietary Supplement: Placebo drink |
| Non-liposomal collagen drink | Active comparator | Not described Receives: Dietary Supplement: Non-liposomal collagen drink |
| Liposomal collagen drink | Experimental | Not described Receives: Dietary Supplement: Liposomal collagen drink |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change of skin collagen density
DermaLab® Series SkinLab Combo was utilized to measure skin collagen density. Units: arbitrary units
Measured: Change from Baseline skin collagen density at 8 weeks
The change of skin wrinkles
VISIA Complexion Analysis was utilized to measure skin wrinkles. Units: the amount of detectable wrinkles
Measured: Change from Baseline skin wrinkles at 8 weeks
The change of skin elasticity
Cutometer® MPA580 was utilized to measure skin elasticity. Units: arbitrary units
Measured: Change from Baseline skin elasticity at 8 weeks
Secondary outcomes (4)
The change of wrinkles around the eyes
VISIA Complexion Analysis was utilized to measure wrinkles around the eyes. Units: the amount of detectable wrinkles
Measured: Change from Baseline wrinkles around the eyes at 8 weeks
The change of skin hydration
Corneometer® CM825 (CK, Germany) was utilized to measure skin surface hydation. Units: arbitrary Corneometer® units 0-120.
Measured: Change from Baseline skin hydration at 8 weeks
The change of skin lightness
Chroma Meter MM500 was utilized to measure face skin lightness. Units: L* index
Measured: Change from Baseline skin lightness at 8 weeks
The change of skin tone
Chroma Meter MM500 was utilized to measure face skin color. Units: Individual Typology Angle (ITA°)
Measured: Change from Baseline skin tone at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2025
- Study start1 Nov 2024
- Primary completion24 Jan 2025
- Study completion28 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Skin ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Chia-Hua Liang, Ph.D., Principal investigator, Chia Nan University of Pharmacy ＆ Science
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06771388
- Sponsor's protocol ID
- 24-088-B
- Status last verified
- Apr 2025
- First submitted
- 8 Jan 2025
- Last updated
- 13 Apr 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Lin YK, Liang CH, Huang BC, Lim SH, Lin YH, Chan ST, Chiang CF, Mao YW. Liposomal Delivery Enhances the Effects of a Collagen Tripeptide-Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double-Blind, Placebo-Controlled Trial. J Cosmet Dermatol. 2026 Apr;25(4):e70834. doi: 10.1111/jocd.70834.
PubMed 41918155
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy Evaluation of Avance QQ Collagen for Skin Beautification
- ClinicalTrials.gov ID
- NCT06771388
- Acronym / sponsor ID
- 24-088-B
- Conditions
- Skin Condition, Liposomal Encapsulation
- Keywords
- Avance QQ Collagen, Double Nutri
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 24 Jan 2025 (actual)
- Study completion
- 28 Feb 2025 (actual)
- First posted
- 13 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess Avance QQ Collagen product on skin condition improvement
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo drink | Placebo comparator | Dietary Supplement: Placebo drink |
| Non-liposomal collagen drink | Active comparator | Dietary Supplement: Non-liposomal collagen drink |
| Liposomal collagen drink | Experimental | Dietary Supplement: Liposomal collagen drink |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy male or female adults, age above 18 years old;
- The grade of crow's feet above 2 (Han et al. Sci Rep 13, 18903 (2023));
- Commitment not to use products having activity comparable with that of the product to be tested during the study period;
- Free of any dermatological or systemic disorder that would interfere with results.
Key exclusion criteria (5 listed)
- Subject with obvious skin surface damage;
- Subject who had oral or topical medication which may affect skin condition within 1 month;
- Subject who is a vegetarian or likely to be acutely allergic to the listed ingredients in the product;
- Female who is pregnant, nursing or planning to become pregnant during the course of the study;
- Received facial laser therapy, chemical peeling in the past 2 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liposomal collagen drinkAlso: Avance QQ Collagenconsume 50 g liquid drink daily for 8 consecutive weeks | Dietary supplement | Liposomal collagen drink |
| Non-liposomal collagen drinkconsume 50 g liquid drink daily for 8 consecutive weeks | Dietary supplement | Non-liposomal collagen drink |
| Placebo drinkconsume 50 g liquid drink daily for 8 consecutive weeks | Dietary supplement | Placebo drink |
Primary outcome
The change of skin collagen density
Time frame: Change from Baseline skin collagen density at 8 weeks
DermaLab® Series SkinLab Combo was utilized to measure skin collagen density. Units: arbitrary units
The change of skin wrinkles
Time frame: Change from Baseline skin wrinkles at 8 weeks
VISIA Complexion Analysis was utilized to measure skin wrinkles. Units: the amount of detectable wrinkles
The change of skin elasticity
Time frame: Change from Baseline skin elasticity at 8 weeks
Cutometer® MPA580 was utilized to measure skin elasticity. Units: arbitrary units
4 secondary outcomes
The change of wrinkles around the eyes
Time frame: Change from Baseline wrinkles around the eyes at 8 weeks
The change of skin hydration
Time frame: Change from Baseline skin hydration at 8 weeks
The change of skin lightness
Time frame: Change from Baseline skin lightness at 8 weeks
The change of skin tone
Time frame: Change from Baseline skin tone at 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2025.
- Derived from this study: PubMed 41918155Lin YK, Liang CH, Huang BC, Lim SH, Lin YH, Chan ST, Chiang CF, Mao YW. Liposomal Delivery Enhances the Effects of a Collagen Tripeptide-Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double-Blind, Placebo-Controlled Trial. J Cosmet Dermatol. 2026 Apr;25(4):e70834. doi: 10.1111/jocd.70834.
Related trials for Skin Condition
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chia-Hua Liang, Ph.D. principal investigator
Chia Nan University of Pharmacy ＆ Science
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Liposomal collagen drink and Non-liposomal collagen drink in people with Skin Condition and Liposomal Encapsulation, run by TCI Co., Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change of skin collagen density (time frame: Change from Baseline skin collagen density at 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06771388, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2025.